Fosun Pharma (HKEX: 02196) has announced that on September 14, 2026, the company repurchased 1.455 million shares at a total cost of HK$24.7051 million.

The buyback reflects the company's ongoing capital management strategy, aimed at enhancing shareholder value. The repurchased shares are expected to be canceled or held as treasury stock, depending on regulatory requirements and the board's discretion.

This transaction underscores Fosun Pharma's commitment to optimizing its capital structure while maintaining sufficient liquidity for future growth initiatives.